I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

In a recent move at Akero Therapeutics, Inc. (NASDAQ: AKRO), Chief Development Officer Yale Catriona sold shares worth more than $150,000. The transaction, which took place on September 20, 2024, ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Akero Therapeutics has been a focus of several analyst firms. Canaccord Genuity maintained a Buy rating on the company's stock, noting the potential of the drug candidate, Efruxifermin.

Akero Therapeutics, Inc. (NASDAQ: AKRO) President and CEO Andrew Cheng recently sold shares in the company, yielding a total of $178,728. The transaction, which took place on June 11, involved the ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

In a recent SEC filing, Rolph Timothy, Chief Scientific Officer of Akero Therapeutics, Inc. (NASDAQ: AKRO), disclosed the sale of company shares valued at approximately $1.74 million. The transactions ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands ...

Akero Therapeutics’ (NASDAQ:AKRO) is a good candidate for a basket of MASH players. The company’s EFX has differentiated itself well in pre-cirrhotic MASH, and the 96-week data may change the ...

By Reuters March 30, 20209:10 PM UTCUpdated ago March 30 (Reuters) - Akero Therapeutics Inc: * AKERO THERAPEUTICS TO ANNOUNCE RESULTS FOR WEEK 12 EFFICACY ENDPOINTS FROM NASH PHASE 2A BALANCED ...

* AKERO THERAPEUTICS INC QTRLY LOSS PER SHARE $0.42 * AKERO THERAPEUTICS - EXPECTS TO HAVE DRUG PRODUCT AVAILABLE IN Q4 2020 TO SUPPLY PHASE 2B PORTION OF PHASE 2B/3 CLINICAL TRIAL BEGINNING IN H1 ...